Editorial Board About Us

Benjamin H. Lowentritt

All articles from this author are listed below.

Volume 23, Number 3 Meet The Expert

Meet the Expert: Shelby Moneer, MS, CHES, from ZERO Prostate Cancer

Benjamin H. Lowentritt

Thank you for joining us today for our third “Meet the Expert” session with our special guest Shelby Moneer. Shelby is vice president of patient programs and education at ZERO Prostate Cancer. I’m your moderator for today, Benjamin Lowentritt. I’m the medical director of the prostate cancer program at Chesapeake Urology, and I am fortunate enough to be one of the medical advisors for ZERO, as well. Today’s “Meet the Expert” is sponsored by Cipla. For more information about Cipla, please visit their website at www.cipla.com.

Prostatic neoplasms patient advocacy

Volume 23, Number 2 Prostate Cancer

Real-World Comparison of Deep Prostate-Specific Antigen Response in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Apalutamide or Enzalutamide

Benjamin H. Lowentritt Ibrahim Khilfeh Dominic Pilon Shawn Du Carmine Rossi Frederic Kinkead Lilian Diaz Jill Korsiak Patrick Lefebvre Gordon A Brown

Deep prostate-specific antigen reduction of at least 90% (PSA90 response) after androgen receptor pathway inhibitor initiation to treat metastatic castration-sensitive prostate cancer (mCSPC) is associated with longer survival. This real-world study evaluated the proportion of androgen receptor pathway inhibitor–naive patients with mCSPC who achieved PSA90 response 6 months after initiating apalutamide or enzalutamide.

Prostatic neoplasms Prostate-specific antigen (PSA)Prostate-specific antigen Prostate-specific antigens Castration Androgen receptor Androgen receptor antagonists treatment effectiveness

Volume 23, Number 1 Prostate Cancer

Specialty Networks Unveils Revised Advanced Prostate Cancer Clinical Guidelines

David Morris Benjamin H. Lowentritt

In an ongoing effort to support independent urology practices’ work to provide first-class cancer care, Specialty Networks recently unveiled new, expanded clinical guidelines for advanced prostate cancer (PCa) treatment. (See the guidelines, packaged with this issue of Reviews in Urology.)

Prostatic neoplasms Neoplasm practice guidelines clinical decision-making